Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis | Zendy

Eli O. Meltzer | Zendy; Paul H. Ratner | Zendy; Claus Bachert | Zendy; Warner Carr | Zendy; William E. Berger | Zendy; Giorgio Walter Caica | Zendy; James A. Hadley | Zendy; Phil Lieberman | Zendy; Frank C. Hampel | Zendy; Joaquim Mullol | Zendy; Ullrich Munzel | Zendy; David Price | Zendy; Glenis Scadding | Zendy; J. Christian Virchow | Zendy; U. Wahn | Zendy; Ruth Murray | Zendy; Jean Bousquet | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis

Author(s) -

Eli O. Meltzer,

Paul H. Ratner,

Claus Bachert,

Warner Carr,

William E. Berger,

Giorgio Walter Caica,

James A. Hadley,

Phil Lieberman,

Frank C. Hampel,

Joaquim Mullol,

Ullrich Munzel,

David Price,

Glenis Scadding,

J. Christian Virchow,

U. Wahn,

Ruth Murray,

Jean Bousquet

Publication year - 2013

Publication title -

international archives of allergy and immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.696

H-Index - 100

eISSN - 1423-0097

pISSN - 1018-2438

DOI - 10.1159/000351404

Subject(s) - fluticasone propionate , medicine , post hoc analysis , placebo , nasal congestion , nasal spray , nasal administration , nose , surgery , pharmacology , asthma , pathology , alternative medicine

It is unclear what constitutes a clinically meaningful response for allergic rhinitis (AR) outcomes. The objectives of these post hoc analyses were (1) to define a clinically meaningful response using novel efficacy analyses (including a responder analysis), and (2) to compare the efficacy of MP29-02 [a novel intranasal formulation of azelastine hydrochloride (AZE) and fluticasone propionate (FP)] with commercially available FP, AZE and placebo in seasonal AR (SAR) patients, using these novel analyses.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research